Thus, SYK inhibitors are being developed to treat allergic disorders as well as antibody-mediated autoimmune diseases such as allergic rhinitis, rheumatoid arthritis, asthma, cancer, diabetes type I, and immune thrombocytopenia among others. This evidence concerns the gene SYK and autoimmune thrombocytopenic purpura.